Ovarian cancer access efforts grow amid rural barriers

Reports highlight persistent access challenges in ovarian cancer care: rural patients in New Zealand face travel, cost and logistical barriers to diagnosis and treatment, while nearly half of national cases in the past year were identified through emergency or unplanned hospital care, where mortality in the following year was twice as high. A study of 44 patients with rare, aggressive ovarian carcinosarcoma found that confirmed treatment declined after first-line therapy, with fewer than one in five reaching a third line or later; the researchers also documented varied treatments and a median overall survival of 23.1 months. In Canada, a manufacturer and the pan-Canadian drug alliance reached a deal on Elahere, bringing eligible patients with platinum-resistant ovarian cancer closer to public coverage, though provincial and territorial reimbursement steps remain. In Kentucky, UK HealthCare is expanding free ovarian cancer screenings through partnerships with local hospitals and health departments to bring care closer to women.